Trinity Wealth Management LLC Has $2.02 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Trinity Wealth Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 12,206 shares of the company’s stock after purchasing an additional 810 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Trinity Wealth Management LLC’s holdings, making the stock its 19th biggest position. Trinity Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,024,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Tallon Kerry Patrick acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $290,000. Capital & Planning LLC lifted its holdings in Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after purchasing an additional 183 shares during the last quarter. Brighton Jones LLC raised its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson in the 4th quarter valued at $85,886,000. Finally, Blossom Wealth Management raised its holdings in Johnson & Johnson by 6.4% in the 4th quarter. Blossom Wealth Management now owns 2,317 shares of the company’s stock valued at $335,000 after acquiring an additional 140 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.7%

NYSE JNJ opened at $153.39 on Thursday. The business’s 50-day moving average price is $153.81 and its two-hundred day moving average price is $153.67. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market capitalization of $369.07 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.39%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s payout ratio is currently 57.84%.

Analysts Set New Price Targets

Several equities analysts have weighed in on JNJ shares. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Raymond James decreased their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.